LB Pharmaceuticals Inc
LBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. At a $1.25B market cap, LB Pharmaceuticals Inc ranks as a small-cap company within healthcare. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Market Cap
$1.25B
Beta
—
P/E (TTM)
387.30
P/E (Fwd)
-7.55
EPS (TTM)
$0.10
EPS (Fwd)
$-5.13
ROE
-50.0%
ROA
-30.0%
Cash
$327.8M
Total Debt
$5.2M
Free CF
-$53.9M
52W Change
131.9%
Annual Financials
Cash vs Debt
Where LBRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LBRX finished 12.04% above its 150-day moving average ($34.64) and 22.43% above its 200-day moving average ($31.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LBRX overbought or oversold?
At the October 20, 2026 close, LBRX's RSI(14) was 54.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
LB Pharmaceuticals Inc holds $327.8M in cash against $5.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$53.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -50.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. At over 50x earnings, LBRX carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence LB Pharmaceuticals Inc's trajectory.